Jafar Moininazeri's profile picture

Jafar Moininazeri

Scientist I at RayzeBio

Jafar Moininazeri has a diverse work experience spanning different fields. Jafar is currently working at RayzeBio as a Scientist I. Prior to this, they worked at Bristol Myers Squibb as a Research Scientist, where they conducted in vivo pharmacology studies, optimized cell-based immunoassays, and was an expert in drug dosing for animal models. Before that, they were a Senior Research Assistant at UC San Diego Health, where they focused on in vivo and in vitro drug discovery for osteoporosis treatment. Jafar skillfully managed murine experimentation, obtained DNA and extracted RNA for genetic analysis, established and maintained primary osteoblast cell lines, and implemented various assays to evaluate cellular processes. Earlier in their career, Jafar served as a Hospital Corpsman in the US Navy, where they provided emergency medical care and trained personnel in first aid and record maintenance.

Jafar Moininazeri's education history begins in 2009 when they obtained a certification in Police Officer Standard Training from Riverside City College.

From 2014 to 2016, Jafar attended Fullerton College where they earned multiple Associate's degrees. These degrees include Biology, Chemistry, IDC: Math & Science, and IDC: Art & Human Expression.

In 2016, Jafar advanced their education at UC San Diego and earned a Bachelor of Science (BS) degree in Molecular Biology, which they completed in 2018.

Continuing their education at UC San Diego, Jafar pursued a Master of Science (MS) degree in Biomedical Sciences from 2018 to 2020.

Based on the provided information, Jafar's education history shows a progression from obtaining certifications and Associate's degrees to completing a Bachelor's degree in Molecular Biology and finally earning a Master's degree in Biomedical Sciences.

Location

San Diego, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


R

RayzeBio

1 followers

RayzeBio is a leader in targeted radiopharmaceuticals to improving cancer patient survival. The broad pipeline of innovative drugs against solid tumor targets.


Industries

Employees

51-200

Links